Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Moodys
Baxter
US Department of Justice
Covington

Generated: August 20, 2019

DrugPatentWatch Database Preview

BALVERSA Drug Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which patents cover Balversa, and what generic alternatives are available?

Balversa is a drug marketed by Janssen Biotech and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-seven patent family members in thirty-seven countries.

The generic ingredient in BALVERSA is erdafitinib. One supplier is listed for this compound. Additional details are available on the erdafitinib profile page.

Summary for BALVERSA
International Patents:77
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Drug Prices: Drug price information for BALVERSA
DailyMed Link:BALVERSA at DailyMed
Drug patent expirations by year for BALVERSA
Generic Entry Opportunity Date for BALVERSA
Generic Entry Date for BALVERSA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for BALVERSA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-001 Apr 12, 2019 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-002 Apr 12, 2019 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-001 Apr 12, 2019 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-003 Apr 12, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-002 Apr 12, 2019 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Colorcon
Merck
Daiichi Sankyo
Farmers Insurance
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.